Paul Fortin

Dr. Fortin joined the staff of Toronto Western Division/University Health Network (UHN) and Research Institute in 2000 as a Clinician Scientist and Director of Clinical Research for the Arthritis Centre of Excellence. He became Full Professor of Medicine at the University of Toronto in 2007 and held cross-appointments as staff at the Hospital for Sick Children and as Associate Professor at the Institute of Medical Sciences and the Department of Health Policy, Management and Evaluation of the University of Toronto. In August 2011, he moved to Quebec City, Canada and became Full Professor with tenure at Université Laval and Clinician-Scientist at the ‘Centre de Recherche du Centre Hospitalier Universitaire de Québec’. He’s held a senior Canada Research Chair on Systemic Autoimmune Rheumatic Diseases since 2012.

Dr. Fortin has been working on a better understanding of the bio-psycho-social impact of chronic rheumatic diseases such as systemic lupus erythematosus (SLE), the antiphospholipid antibody syndrome (APS), systemic autoimmune rheumatic diseases (SARD) and rheumatoid arthritis. He is particularly interested in clinical applications of translational research and in developing interventions for the treatment of SLE, APS and SARD.

His methodological interests cover the development and validation of health status measures and other clinical tools such as measures of disease activity or damage in SLE. His other methodological interests include the development of risk profiles for arterial or venous thrombosis in APS, the testing of treatments of disease activity or cardiovascular disease in SLE, or the validation of biological markers in SLE and SARD.

In 1995, he created the Canadian Network for Improved Outcomes in SLE (CaNIOS) with the specific goal of running a multi-centre, randomized, and controlled Study of Methotrexate in Lupus Erythematosus (SMILE).  CaNIOS brought together many lupus experts who, despite their limited individual cohorts, were able to pool information for the completion of SMILE.  CaNIOS has conducted several CIHR and TAS funded national studies, including the project on ‘Empowering Patients as Active Partners in Their Care: Lupus Interactive Navigator (LIN)’, ‘The Dissemination of the Lupus Health Passport’, ‘Health Improvement and Prevention Program for Persons with SLE’ (HIPP study), ‘Lupus Nephritis New Emerging Team’ (LuNNET), ‘Genetic and Environmental Factors in SLE’ (GenES Study), and ‘Role of Thrombophilic Factors in Persons with SLE’ (ThromboFIL study). Also, CaNIOS is building a national database, a clinical trial infrastructure through support from the Lupus Clinical Trial Consortium and a training environment for young researchers.

Since 2011, Dr. Fortin is building an arthritis multidisciplinary research infrastructure based on the SARD Database and Biobank hosted by Université Laval and that has been a catalyst for translational research on SLE and rheumatoid arthritis locally and nationally. His efforts have culminated in the recent creation of the Centre ARThrite, which is one of the few scientific centres recognized and supported by Université Laval.

With the arrival of the COVID-19 pandemic, Dr Fortin has undertaken research projects to evaluate the safety and efficacy of COVID-19 vaccination in patients living with SARD.

Dr. Paul Fortin Publications 

Balbi GGM, Ahmadzadeh Y, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Lopez-Pedrera C,  Fortin PR, Wahl D, Gerosa M, de Jesús GR, Ji L, Atsumi T, Efthymiou M, Branch DW, Nalli C, Almaraz ER, Petri M, Cervera R, Knight JS, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Roubey R, Erkan D, Andrade D; AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (APS ACTION). Damage measured by damage index for antiphosphlipid syndrome in antiphospholipid antibody-positive patients included in APS ACTION Registry. Rheumatology (Oxford). 2023 Jun 12:kead292. doi: 10.1093/rheumatology/kead292. Epub ahead of print. PMID: 37307082.

Lee JE, Mendel A, Askanase A, Bae SC, Buyon JP, Clarke AE, Costedoat-Chalumeau N, Fortin PR, Gladman DD, Ramsey-Goldman R, Hanly JG, Inanç M, Isenberg DA, Mak A, Mosca M, Petri M, Rahman A, Sanchez-Guerrero J, Urowitz M, Wallace DJ, Bernatsky S, Vinet É. Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience. Ann Rheum Dis. 2023 May 19:ard-2023-224197. doi: 10.1136/ard-2023-224197. Epub ahead of print. PMID: 37208152.

Muntyanu A, Milan R, Rahme E, Baron M, Netchiporouk E; Canadian Scleroderma Research Group. Organic Solvent Exposure and Systemic Sclerosis: A Retrospective Cohort Study Based on the Canadian Scleroderma Research Group Registry. J Am Acad Dermatol. 2023 May 12:S0190-9622(23)00781-8. doi: 10.1016/j.jaad.2023.04.062. Epub ahead of print. PMID: 37182702.

Neyer MA, Henry RS, Carrier ME, Kwakkenbos L, Wojeck RK, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Mayes MD, Mouthon L, Nielson WR, Richard M, Worron-Sauvé M, Harel D, Malcarne VL, Bartlett SJ, Thombs BD; SPIN Investigators. Validity, Reliability, and Differential Item Functioning of English and French Versions of the 10-Item Connor-Davidson Resilience Scale in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. Arthritis Care Res (Hoboken). 2023 May 2. doi: 10.1002/acr.25139. Epub ahead of print. PMID: 37128826.

Choi MY, Chen I, Clarke AE, Fritzler MJ, Buhler KA, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Buyon JP, Sontag D, Costenbader KH. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes. Ann Rheum Dis. 2023 Apr 21:ard-2022-223808. doi: 10.1136/ard-2022-223808. Epub ahead of print. PMID: 37085289.

Henry RS, Kwakkenbos L, Carrier ME, Patten S, Bartlett SJ, Mouthon L, Varga J, Benedetti A, Thombs BD; SPIN COVID-19 Patient Advisory Team for the SPIN Investigators. Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study. Clin Exp Rheumatol. 2023 Apr 19. doi: 10.55563/clinexprheumatol/cca0xv. Epub ahead of print. PMID: 37083160.

Gkrouzman E, Willis R, Andrade D, Tektonidou MG, Pengo V, Ruiz-Irastorza G, Belmont HM, Fortin PR, Gerosa M, Signorelli F, Atsumi T, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri MA, Cervera R, Knight JS, Efthymiou M, Cohen H, Bertolaccini ML, Erkan D, Roubey R; APS ACTION. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An APS ACTION Study. Lab Invest. 2023 Apr 10:100147. doi: 10.1016/j.labinv.2023.100147. Epub ahead of print. PMID: 37044248.

Rapoport C, Choi AK, Kwakkenbos L, Carrier ME, Henry RS, Mouthon L, Roesch SC, Thombs BD, Malcarne VL; SPIN COVID-19 Patient Advisory Team; SPIN Investigators. Evaluation of Measurement Properties and Differential Item Functioning in English and French Versions of the UCLA Loneliness Scale-6: A Scleroderma Patient-Centered Intervention Network (SPIN) Study. Arthritis Care Res (Hoboken). 2023 Mar 20. doi: 10.1002/acr.25115. Epub ahead of print. PMID: 36938696.

Zuo Y, Navaz S, Tsodikov A, Kmetova K, Kluge L, Ambati A, Hoy CK, Yalavarthi S, de Andrade D, Tektonidou MG, Sciascia S, Pengo V, Ruiz-Irastorza G, Belmont HM, Gerosa M, Fortin PR, de Jesus GR, Branch DW, Andreoli L, Rodriguez-Almaraz E, Petri M, Cervera R, Willis R, Karp DR, Li QZ, Cohen H, Bertolaccini ML, Erkan D, Knight JS; APS ACTION. Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository. Arthritis Rheumatol. 2023 Mar 2. doi: 10.1002/art.42489. Epub ahead of print. PMID: 36862141.

Wurz A, Duchek D, Ellis K, Bansal M, Carrier ME, Tao L, Dyas L, Kwakkenbos L, Levis B, El-Baalbaki G, Rice DB, Wu Y, Henry RS, Bustamante L, Harb S, Hebblethwaite S, Patten SB, Bartlett SJ, Varga J, Mouthon L, Markham S, Thombs BD, Culos-Reed SN; SPIN-CHAT Patient Advisory Team; Program Facilitators; Scleroderma Patient-centered Intervention Network Investigators. A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: perceptions of trial participants and research team members. Disabil Rehabil. 2023 Jan 28:1-13. doi: 10.1080/09638288.2023.2169775. Epub ahead of print. PMID: 36708187.

Chighizola CB, Pregnolato F, Andrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont HM, Gerosa M, Fortin P, Branch DW, Andreoli L, Petri MA, Cervera R, Knight JS, Willis R, Efthymiou M, Cohen H, Erkan D, Bertolaccini ML; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). Fluctuation of Anti-Domain 1 and Anti-β2 -Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies. Arthritis Rheumatol. 2023 Jun;75(6):984-995. doi: 10.1002/art.42459. Epub 2023 Apr 2. PMID: 36704930.

Clarke AE, Hanly JG, Urowitz MB, St Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, Van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling. Arthritis Care Res (Hoboken). 2023 Jan 24. doi: 10.1002/acr.25090. Epub ahead of print. PMID: 36691838.

Hazlewood G , Colmegna I, Hitchon C, Fortin PR, Bernatsky S, Clarke A E, Mosher D, Wilson T, Thomas M, Barber C, Harrison M, Bansback N, Proulx L, Richards D P, Kaplan G G. (2023) Preferences for COVID-19 vaccination in people with chronic immune-mediated inflammatory diseases. J Rheumatol. 2023 jan. 220697. doi: 10.3899/jrheum.220697. PMID: 36642432

Baron M, Barbacki A, Man A, de Vries-Bouwstra JK, Johnson D, Stevens W, Osman M, Wang M, Zhang Y, Sahhar J, Ngian GS, Proudman S, Nikpour M; Australian Scleroderma Interest Group; Canadian Scleroderma Research Group. Prediction of Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling. Rheumatology (Oxford). 2023 Jan 10:kead002. doi: 10.1093/rheumatology/kead002. Online ahead of print. PMID: 36625513.

Michou L, Julien AS, Witteman HO, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Chetaille AL, Fortin PR. Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial. Arch Rheumatol. 2021 Dec 24;37(2):169-179. doi: 10.46497/ArchRheumatol.2022.8965. PMID: 36017212; PMCID: PMC9377171.

Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 Nov;81(11):1541-1548. doi: 10.1136/ard-2022-222487. Epub 2022 Aug 9. PMID: 35944946.

Muntyanu A, Milan R, Rahme E, LaChance A, Ouchene L, Cormier M, Litvinov IV, Hudson M, Baron M, Netchiporouk E; Canadian Scleroderma Research Group. Exposure to silica and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group. Front Med (Lausanne). 2022 Sep 29;9:984907. doi: 10.3389/fmed.2022.984907. PMID: 36250083; PMCID: PMC9556811.

Kwakkenbos L, Carrier ME, Welling J, Levis B, Levis AW, Sauve M, Turner KA, Tao L, Aguila K, Carboni-Jiménez A, Cañedo-Ayala M, Harb S, van den Ende C, Hudson M, van Breda W, Nguyen C, Boutron I, Rannou F, Thombs BD, Mouthon L; Enquêteurs SPIN. Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial. PMID: 36510233 PMCID: PMC9742661 DOI: 10.1186/s13063-022-06923-4.

Fortin PR, Neville C, Julien AS, Rahme E, Haroun V, Nimigon-Young J, Morrison AL, Eng D, Peschken CA, Vinet E, Hudson M, Smith D, Matsos M, Pope JE, Clarke AE, Keeling S, Avina-Zubieta JA, Rochon M, Da Costa D. Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study. Arthritis Care Res (Hoboken). 2023 Mar;75(3):529-539. doi: 10.1002/acr.24871. Epub 2022 Nov 17. PMID: 35225436.

Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri MA, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Jönsen A, Kamen DL, Aranow C, Sánchez-Guerrero J, Gladman DD, Fortin PR, Alarcon GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase AD, Khamashta M, Bruce IN, Inanc M, Lukusa L, Bernatsky S. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine. Lupus Sci Med. November 2022. PMID: 36396267 DOI: 10.1136/lupus-2022-000789.

Cardwell FS, Elliott SJ, Chin R, St Pierre Y, Choi MY, Urowitz MB, Ruiz-Irastorza G, Bernatsky S, Wallace DJ, Petri MA, Manzi S, Bae SC, Shin JM, Mak A, Cho J, Peschken CA, Ramsey-Goldman R, Fortin PR, Hanly JG, Pons-Estel BA, Nieto R, Askanase AD, Romero-Diaz J, Mosca M, Bruce IN, Rowbottom L, Mielczarek L, Tse K, Marion A, Cáhiz-González JC, Cattoni TG, Cornet A, Clarke AE. Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic. Lupus Sci Med. 2022 Oct;9(1):e000755. doi: 10.1136/lupus-2022-000755. PMID: 36283746; PMCID: PMC9606736.

Erton ZB, K Leaf R, de Andrade D, Clarke AE, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, Fortin PR, Lopez-Pedrera C, Atsumi T, Zhang Z, Cohen H, Ramires de Jesús G, Branch DW, Wahl D, Andreoli L, Rodriguez-Almaraz E, Petri M, Barilaro G, Zuo Y, Artim-Esen B, Willis R, Quintana R, Vendramini MB, Barber MW, Bertolaccini ML, Roubey R, Erkan D. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Lupus. 2022 Dec; 31(14):1770-1776. doi: 10.1177/09612033221128742. Epub 2022 Oct 7. PMID: 36206383.

Becker YLC, Duvvuri B, Fortin PR, Lood C, Boilard E. The role of mitochondria in rheumatic diseases. Nat Rev Rheumatol. 2022 Nov;18(11):621-640. doi: 10.1038/s41584-022-00834-z. Epub 2022 Sep 29. PMID: 36175664.

Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 Nov;81(11):1541-1548. doi: 10.1136/ard-2022-222487. Epub 2022 Aug 9. PMID: 35944946.

Haraoui B, Khraishi M, Choquette D, Lisnevskaia L, Teo M, Kinch C, Galos C, Roy P, Gruben D, Woolcott JC, Vaillancourt J, Sampalis JS, Keystone EC; Canadian Tofacitinib for Rheumatoid Arthritis Observational Investigators. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study. Arthritis Care Res (Hoboken). 2023 Feb; 75(2):240-251. doi: 10.1002/acr.24966. Epub 2022 Oct 10. PMID: 35678771.

Whittall-Garcia L, Goliad K, Kim M, Bonilla D, Gladman D, Urowitz M, Fortin PR, Atenafu EG, Touma Z, Wither J. Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis. Front Immunol (2022 May) 30;13:889931. doi: 10.3389/fimmu.2022.889931. PMID: 35711439

Nevskaya T, Martin Calderon L, Baron M, Pope JE; Canadian Scleroderma Research Group. Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers. Arthritis Care Res (Hoboken). 2022 Apr 19. doi: 10.1002/acr.24902. Online ahead of print.PMID: 35439364

Fortin PR, Da Costa D, Neville C, Julien AS, Rahme E, Haroun V, Singer W, Nimigon-Young J, Morrison AL, Eng D, Peschken CA, Vinet E, Hudson M, Smith D, Matsos M, Pope JE, Clarke AE, Keeling S, Avina-Zubieta JA, Rochon M. Challenges of Perceived Self-Management in Lupus. Arthritis Care Res (Hoboken). 2022 Jul; 74(7):1113-1121. doi: 10.1002/acr.24542. Epub 2022 Apr 13.PMID: 33342087

Choi M, Clarke A, Costenbader K, Urowitz M, Hanly J, Gordon C, St. Pierre Y, Bae S, Romero-Díaz J, Sanchez-Guerrero F, Bernatsky S, Wallace D, Isenberg D, Rahman A, Merrill J, Fortin P, Gladman D, Bruce I, Petri M, Ginzler E, Dooley M, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón G, Van Vollenhoven R, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen D, Askanase A, Fritzler M. Longitudinal Analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort . Annals of the Rheumatic Diseases. Aug; 81(8):1143-1150. doi: 10.1136/annrheumdis-2022-222168

Erton B, Sevim E, de Jesus GR, Pengo V, Cervera R, Andrade D, Fortin PR, Atsumi T, Knight J, Petri M, Branch W, Erkan D and AL on Behalf of APS ACTION. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION Clinical Database and Repository (“Registry”). Lupus Science & Medicine. 2022 Jun;9(1):e000633. doi: 10.1136/lupus-2021-000633, PMID: 35701043 PMCID: PMC9198709.

Hasse S, Julien AS, Duchez AC, Zhao C, Boilard E, Fortin PR, Bourgoin SG. Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus. Lupus Sci Med. 2022 Mar;9(1):e000605. doi: 10.1136/lupus-2021-000605. PMID: 35260475; PMCID: PMC8905995.

Michou L, Julien AS, Witteman HO, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Chetaille AL, Fortin PR. Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial. Arch Rheumatol. 2021 Dec 24;37(2):169-179. doi: 10.46497/ArchRheumatol.2022.8965. PMID: 36017212; PMCID: PMC9377171.

Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling. Arthritis Care Res (Hoboken). 2023 Mar;75(3):640-647. doi: 10.1002/acr.24873. Epub 2022 Nov 15. PMID: 35226416.

Caron P, Nguyen Van Long F, Rouleau M, Bujold E, Fortin P, Mohammadi S, Lévesque É, Breton S, Guillemette C. A liquid chromatography-mass spectrometry assay for the quantification of nucleotide sugars in human plasma and urine specimens and its clinical application. J Chromatogr 2022 Aug 16;1677:463296. doi: 10.1016/j.chroma.2022.463296. Epub 2022 Jul 1. PMID: 35820232.

Kwakkenbos L, Østbø N, Carrier ME, Nielson WR, Fedoruk C, Levis B, Henry RS, Pope J, Frech T, Gholizadeh S, Johnson SR, Piotrowski P, Jewett LR, Gordon J, Chung L, Bilsker D, Tao L, Turner KA, Cumin J, Welling J, Fortuné C, Leite C, Gottesman K, Sauvé M, Reyna TSR, Hudson M, Larche M, van Breda W, Suarez-Almazor ME, Bartlett SJ, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Benedetti A, Thombs BD; SPIN Investigators. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot Feasibility Stud. 2022 Feb 26;8 (1):45. doi: 10.1186/s40814-022-00994-5.PMID: 35219340

Becker YLC, Gagné JP, Julien AS, Lévesque T, Allaeys I, Gougeard N, Rubio V, Boisvert FM, Jean D, Wagner E, Poirier GG, Fortin PR, Boilard É. Identification of Mitofusin 1 and Complement Component 1q Subcomponent Binding Protein as Mitochondrial Targets in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 Jul;74(7):1193-1203. doi: 10.1002/art.42082. Epub 2022 Jun 6. PMID: 35128841.

Hamoudi C, Zhao C, Abderrazak A, Salem M, Fortin PR, Sévigny J, Aoudjit F. The Purinergic Receptor P2X4 Promotes Th17 Activation and the Development of Arthritis. J Immunol. 2022 Mar 1;208(5):1115-1127. doi: 10.4049/jimmunol.2100550. Epub 2022 Feb 14. PMID: 35165166.

Michou L, Julien AS, Witteman HO, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Chetaille AL, Fortin PR. Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial. Arch Rheumatol. 2021 Dec 24;37(2):169-179. doi: 10.46497/ArchRheumatol.2022.8965. PMID: 36017212; PMCID: PMC9377171.

Mainville L, Smilga AS, Fortin PR. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis. J Cutan Med Surg. 2022 May-Jun;26(3):297-308. doi: 10.1177/12034754221078201. Epub 2022 Feb 8. PMID: 35134311; PMCID: PMC9125143.

Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB, Gladman D, Nived O, Romero-Diaz J, Petri M, Ginzler E, Fortin PR, Bae SC, Wallace DJ, Yelin EH, Bernatsky S. Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment. Lupus. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28595511

Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, Bernatsky S, Bruce I, Buyon J, Cervera R, Clarke A, Dooley MA, Fortin P, Ginzler E, Gladman D, Hanly J, Inanc M, Jacobsen S, Kamen D, Khamashta M, Lim S, Manzi S, Nived O, Peschken C, Petri M, Kalunian K, Rahman A, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K, Sturfelt G, Urowitz M, van Vollenhoven R, Wallace DJ, Zoma A, Merrill J, Gordon C (2017) A study of flare assessment in systemic  lupus erythematosus (SLE) based on paper patients. Arthritis Care Res (Hoboken). [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28388813

Choi MY, Clarke AE, St. Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Buyon J, Mahler M, Fritzler MJ (2017) The Prevalence and Determinants of Anti-DFS70 Autoantibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients. Lupus, 0: 1-9. https://www.ncbi.nlm.nih.gov/pubmed/28420054

Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Huq M, Proudman S, Nikpour M; Canadian Scleroderma Research Group*; Australian Scleroderma Interest Group (2017) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis & Rheumatology, 69(5):1067-1077. https://www.ncbi.nlm.nih.gov/pubmed/28029745

Richard N, Hudson M, Gyger G, Baron M, Sutton E, Khalidi N, Pope JE, Carrier N, Larché M, Albert A, Fortin PR, Thorne C, Masetto A; on the behalf of Canadian Scleroderma Research Group* (2017) Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology (Oxford). 56(4):581-588. https://www.ncbi.nlm.nih.gov/pubmed/28013205

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE (2017) Breast cancer in systemic lupus. Lupus, 26(3): 311-315. https://www.ncbi.nlm.nih.gov/pubmed/27687028

Li G, Adachi JD, Cheng J, Thabane L, Hudson M, Fritzler MJ, Lorenzi S, Baron M, Larché M; Canadian Scleroderma Research Group* (2017) Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28229818

Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Harcourt D, Rumsey N, Mayes MD, Assassi S, Körner A, Fox RS, Gholizadeh S, Mills SD, Fortune C, Thombs BD; SPIN^∆ Investigators (2017) Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 20: 99-106. https://www.ncbi.nlm.nih.gov/pubmed/28068643

Levis AW, Harel D, Kwakkenbos L, Carrier ME, Mouthon L, Poiraudeau S, Bartlett SJ, Khanna D, Malcarne VL, Sauve M, van den Ende CH, Poole JL, Schouffoer AA, Welling J, Thombs BD; and the Scleroderma Patient-Centered Intervention Network^∆ Investigators (2016) Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res (Hoboken), 68(11):1704-1713. https://www.ncbi.nlm.nih.gov/pubmed/27015290

Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, Molnar JC, Rice DB, Thombs BD; and the SPIN^∆ Investigators (2016) Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Clinical and Experimental Rheumatology, 34 Suppl 100(5): 92-99. https://www.ncbi.nlm.nih.gov/pubmed/27494308

Riehm KE, Kwakkenbos L, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Nielsen K, Baron M, Frech T, Hudson M, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, Thombs BD; Scleroderma Patient-Centered Intervention Network^∆ Investigators (2016) Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care & Research (Hoboken), 68(8): 1195-200. https://www.ncbi.nlm.nih.gov/pubmed/26619042

Hudson M, Luck Y, Stephenson M, Choi MY, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group* (CSRG) (2016) Anti-HMGCR antibodies in systemic sclerosis. Medicine (Baltimore), 95(44): e5280. https://www.ncbi.nlm.nih.gov/pubmed/27858897

Leclair V, Regardt M, Wojcik S, Hudson M; Canadian Inflammatory Myopathy Study^± (CIMS) (2016) Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS One, 9; 11(8):e0160753. https://www.ncbi.nlm.nih.gov/pubmed/27504827

Landolt-Marticorena C, Prokopec SD, Morrison S, Noamani B, Bonilla D, Reich H, Scholey J, Avila-Casado C, Fortin PR, Boutros PC, Wither J. (2016) A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Research & Therapy, 4; 18(1): 218. https://www.ncbi.nlm.nih.gov/pubmed/27716443

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V (2016) A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis & Rheumatology, 68(8):1932-44. https://www.ncbi.nlm.nih.gov/pubmed/26991067

Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin PR, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford), 55(2): 252-62. https://www.ncbi.nlm.nih.gov/pubmed/26342222

Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group* (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS) (2016) Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore), 95(35): e4713. https://www.ncbi.nlm.nih.gov/pubmed/27583908

Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD; Canadian Scleroderma Research Group* (2016) Development and Validation of the Body Concealment Scale for Scleroderma. Arthritis Care & Research (Hoboken), 68(8): 1158-1165. https://www.ncbi.nlm.nih.gov/pubmed/26663624

Levis B, Rice DB, Kwakkenbos L, Steele RJ, Hagedoorn M, Hudson M, Baron M, Thombs BD; Canadian Scleroderma Research Group* (2016) Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. Arthritis Care & Research (Hoboken), 68(8): 1143-1149. https://www.ncbi.nlm.nih.gov/pubmed/26605870

Valenzuela A, Baron M, Canadian Scleroderma Research Group*, Herrick AL, Proudman S, Stevens W; Australian Scleroderma Interest Group, Rodriguez-Reyna TS, Vacca A, Medsger TA Jr, Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L (2016) Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars in Arthritis and Rheumatism, 46(3): 344-349. https://www.ncbi.nlm.nih.gov/pubmed/27371996

Baron M, Pope J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larché M, Abu-Hakima M, Rodriguez-Reyna TS, Cabral-Castaneda AR, Fritzler MJ, Wang M, Hudson M (2016) Calcinosis is associated with digital ischaemia in systemic sclerosis: a longitudinal study. Rheumatology (Oxford), 55(12): 2148-2155. https://www.ncbi.nlm.nih.gov/pubmed/27593964

Fortin PR, Cloutier N, Bissonnette V, Aghdassi E, Eder L, Simonyan D, Laflamme N, Boilard E (2016) Distinct Subtypes of Microparticle-containing Immune Complexes Are Associated with Disease Activity, Damage, and Carotid Intima-media Thickness in Systemic Lupus Erythematosus. Journal of Rheumatology, 43(11): 2019-2025. https://www.ncbi.nlm.nih.gov/pubmed/27585687

Harel D, Hudson M, Iliescu A, Baron M, Canadian Scleroderma Research Group*, Steele R (2016) Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician’s Global Assessment of Disease Severity in Systemic Sclerosis. Journal of Rheumatology, 43(8): 1510-1518. https://www.ncbi.nlm.nih.gov/pubmed/27307525

Neville C, Da Costa D, Rochon M, Peschken CA, Pineau CA, Bernatsky S, Keeling S, Avina-Zubieta A, Lye E, Eng D, Fortin PR (2016) Development of the Lupus Interactive Navigator as an Empowering Web-Based eHealth Tool to Facilitate Lupus Management: Users Perspectives on Usability and Acceptability. JMIR Research Protocols, 5(2):e44. https://www.ncbi.nlm.nih.gov/pubmed/27240666

George A, Wong-Pak A, Peschken CA, Silverman E, Pineau C, Smith CD, Arbillaga H, Zummer M, Bernatsky S, Hudson M, Hitchon C, Fortin PR, Nevskaya T, Pope JE, 1000 Faces of Lupus Investigators (2016) The influence of education on disease activity and damage in systemic lupus erythematous: Data from the 1000 Canadian Faces of Lupus. Arthritis Care & Research (Hoboken), 69(1): 124-132. https://www.ncbi.nlm.nih.gov/pubmed/27110869

Boilard E, Fortin PR (2016) Connective tissue diseases: Mitochondria drive NETosis and inflammation in SLE. Nature Reviews Rheumatology, 12(4): 195-196. https://www.ncbi.nlm.nih.gov/pubmed/26935279

Widdifield J, Moura CS, Wang Y, Abrahamowicz M, Paterson JM, Huang A, Beauchamp ME, Boire G, Fortin PR, Bessette L, Bombardier C, Hanly JG, Feldman D, Bernatsky S, CAnadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM) (2016) The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. The Journal of Rheumatology, 43(5): 861-868. https://www.ncbi.nlm.nih.gov/pubmed/26879353

Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler BF, Petri M, Bruce IN, Khamashta M, Aranow C, Dooley M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian KC, Ỉnanç M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T (2016) Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Science & Medicine, 3(1):e000143. Erratum in: Lupus Science & Medicine. 3(1):e000143corr1. https://www.ncbi.nlm.nih.gov/pubmed/27099765

Bernatsky S, Smargiassi A, Barnabe C, Svenson LW, Brand A, Martin RV, Hudson M, Clarke AE, Fortin PR, van Donkelaar A, Edworthy S, Bélisle P, Joseph L (2016) Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. Environmental Research, 146: 85-91. https://www.ncbi.nlm.nih.gov/pubmed/26724462

Racine M, Hudson M, Baron M, Nielson WR, Canadian Scleroderma Research Group* (2016) The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. Journal of Pain and Symptom Management, 52(1): 43-53. https://www.ncbi.nlm.nih.gov/pubmed/26876159

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group* (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Baron M, Fritzler MJ (2015) Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity, 48(8): 542-551. https://www.ncbi.nlm.nih.gov/pubmed/26334795

Kwakkenbos L, Minton O, Stone PC, Alexander S, Baron M, Hudson M, Thombs BD; Canadian Scleroderma Research Group* (2015) Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. The Journal of Rheumatology. 42(7): 1156-1162. https://www.ncbi.nlm.nih.gov/pubmed/26034154

Srivastava N, Hudson M, Tatibouet S, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group* (CSRG) (2015) Thinking outside the box–The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Seminars in Arthritis and Rheumatism, 45(2): 184-189. https://www.ncbi.nlm.nih.gov/pubmed/25959492

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ, Canadian Scleroderma Research Group* (CSRG), Australian Scleroderma Cohort Study (ASCS), Genetics versus Environment in Scleroderma Outcome Study (GENISOS) (2015) Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clinical and Experimental Rheumatology, 33(4 Suppl 91): S131-135. https://www.ncbi.nlm.nih.gov/pubmed/26315678

Moura CS, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Boire G, Fortin PR, Bessette L, Bombardier C, Widdifield J, Hanly JG, Feldman D, Maksymowych W, Peschken C, Barnabe C, Edworthy S, Bernatsky S; CAN-AIM (2015)  Early medication use in new-onset rheumatoid arthritis may delay joint replacement:  results of a large population-based study. Arthritis Research & Therapy, 17: 197. https://www.ncbi.nlm.nih.gov/pubmed/26235697

Al Dhanhani AM, Gignac MA, Beaton DE, Su J, Fortin PR (2015) Job Accommodations Availability and Utilization Among People with Lupus:  An Examination of Workplace Activity Limitations and Work Context Factors. Arthritis care & research (Hoboken), 67(11): 1536-1544. https://www.ncbi.nlm.nih.gov/pubmed/26214148

Bruce IN, O’Keefe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven RF, Kalunian KC, Ruis-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB (2015)  Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.  Annals of the Rheumatic Diseases, 74(9): 1706-1713. https://www.ncbi.nlm.nih.gov/pubmed/24834926

Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, Van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, Bruce IN (2015) Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.  Annals of the Rheumatic Diseases, 74(8): 1530-1536. https://www.ncbi.nlm.nih.gov/pubmed/24692585

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2015) Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis & Rheumatology, 67(7): 1837-47. https://www.ncbi.nlm.nih.gov/pubmed/25778456

Bernatsky S, Smargiassi A, Johnson M, Kaplan GG, Barnabe C, Svenson L, Brand A, Bertazzon S, Hudson M, Clarke AE, Fortin PR, Edworthy S, Belisle P, Joseph L (2015) Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environmental Research, 140: 474-478. https://www.ncbi.nlm.nih.gov/pubmed/25988990

*  Dr. Paul R. Fortin is member of the Canadian Scleroderma Research Group (CSRG)

± Dr. Paul R. Fortin is member of the Canadian Inflammatory Myopathy Study (CIMS)

£ Dr. Paul R. Fortin is member of the CANadian Rheumatology Administrative Data Network (CANRAD)

≠ Dr. Paul R. Fortin is member of Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS)

∆ Dr. Paul R. Fortin is member of the Scleroderma Patient-Centered Intervention Network (SPIN)